Literature DB >> 15192063

Studies on the membrane integrity of human sperm treated with a new injectable male contraceptive.

K Chaudhury1, A K Bhattacharyya, S K Guha.   

Abstract

BACKGROUND: The aim of this study was to evaluate the integrity of sperm surface characteristics in the presence of a new male contraceptive, RISUG [1 mg styrene maleic anhydride (SMA)/100 microl dimethylsulphoxide (DMSO) in 1 ml sperm solution].
METHODS: Progressively motile human sperm were treated in vitro with RISUG. The cells were analysed for the release of 5'-nucleotidase (5'-NT) (a plasma membrane marker) using 3 mmol/l 5'-AMP and 3 mmol/l beta-glycerophosphate as substrates. Hyaluronidase (an acrosomal membrane marker) was analysed using hyaluronic acid as a substrate. The contents of free and total acrosin, and % proacrosin (all acrosome markers) were assayed using 0.5 mmol/l alpha-N-benzoyl-L-arginine ethylester (BAEE).
RESULTS: RISUG caused almost complete disintegration of the plasma membrane leading to significant (P < 0.0001) release of 5'-NT into the surrounding media. Complete dissolution of the acrosome with concomitant vesiculation of the membrane system, as judged from the loss of hyaluronidase, was observed. Total acrosin content in the sperm was also reduced to almost 10%, and proacrosin dropped to 13.2% in the presence of RISUG in comparison to 90.2% in control (P < 0.0001), indicating dispersion of acrosomal contents.
CONCLUSION: Under in vitro conditions, RISUG, at a concentration of 1 mg SMA dissolved in 100 microl of DMSO, caused significant damage to the acrosome and its contents, indicating loss of functional ability of sperm. Copyright 2004 European Society of Human Reproduction and Embryology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192063     DOI: 10.1093/humrep/deh332

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Male contraception: Where do we go from here?

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Spermatogenesis       Date:  2011-10-01

Review 2.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 3.  RISUG: an intravasal injectable male contraceptive.

Authors:  N K Lohiya; I Alam; M Hussain; S R Khan; A S Ansari
Journal:  Indian J Med Res       Date:  2014-11       Impact factor: 2.375

4.  Reversibility of Vasalgel™ male contraceptive in a rabbit model.

Authors:  Donald Waller; David Bolick; Elaine Lissner; Christopher Premanandan; Gary Gamerman
Journal:  Basic Clin Androl       Date:  2017-04-05

5.  Safety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): A clinical experience.

Authors:  Radhey Shyam Sharma; Ajit Kumar Mathur; Rajeev Singh; Hem Chandra Das; Gulshan Jeet Singh; Devinder Pal Singh Toor; Sujoy Kumar Guha
Journal:  Indian J Med Res       Date:  2019-07       Impact factor: 2.375

6.  Smart RISUG: a potential new contraceptive and its magnetic field-mediated sperm interaction.

Authors:  Rakhi K Jha; Pradeep K Jha; Sujoy K Guha
Journal:  Int J Nanomedicine       Date:  2009-04-01

7.  Male contraception.

Authors:  Vivek Mathew; Ganapathi Bantwal
Journal:  Indian J Endocrinol Metab       Date:  2012-11

8.  Evaluation of the spermicidal and contraceptive activity of Platycodin D, a Saponin from Platycodon grandiflorum.

Authors:  Zongliang Lu; Leiguang Wang; Rui Zhou; Yi Qiu; Liuna Yang; Chanyu Zhang; Min Cai; Mantian Mi; Hongxia Xu
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.